08:00 , Nov 9, 2015 |  BC Week In Review  |  Clinical News

CAR-T CD20: Phase IIa data

An open-label, Chinese Phase IIa trial in 10 patients with CD20-positive advanced B cell NHL showed that CBM-CD20.1 led to an ORR of 80%, including 5 complete remissions and 3 partial remissions, plus 2 cases...
07:00 , Apr 6, 2015 |  BC Week In Review  |  Clinical News

CAR-T CD20: Clinical trial data

An open-label, Chinese clinical trial in 7 patients with CD20-positive chemotherapy-refractory advanced DLBCL showed that CAR-T CD20 led to an overall response rate (ORR) of 75% in 4 evaluable patients with bulky tumor burden. In...